Comparative Evaluation of BGR-34 and Sitagliptin in Diabetic Subjects - Open Labelled Randomised Parallel Clinical Study

Data publikacji: 02 lut 2022

Zakres stron: 325 - 332

Otrzymano: 05 paź 2020

Przyjęty: 06 mar 2021

DOI: https://doi.org/10.2478/sjecr-2021-0057

Słowa kluczowe

diabetes mellitus, blood glucose regulator-34, DPP-4 inhibitors, hyperglycemia, sitagliptin

© 2021 Ravinder Singh et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.